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Introduction
Sepsis remains the leading cause of death in the medical inten-
sive care unit (MICU) (1). Although inflammatory responses are 
important for host defense against invading microbes, excessive 
inflammation in sepsis can cause severe cell and tissue damage 
and organ dysfunction, leading to death (2). Our recent studies 
suggest that altered plasma metabolic profiles may reflect disease 
severity and predict mortality in critical illnesses such as sepsis (3, 
4). Furthermore, we have shown that the plasma levels of proin-
flammatory cytokines (e.g., IL-18) and circulating mitochondrial 
injury markers, such as mitochondrial DNA, increase in critical 
illness and are predictive of mortality (5, 6).
Emerging evidence suggests the involvement of inflam-
masomes in the pathogenesis of human diseases, including sepsis 
(7). Inflammasomes are molecular platforms for the caspase-1–
dependent maturation and secretion of proinflammatory cytokines 
such as IL-1β and IL-18 in immune cells (8). Cytoplasmic receptors 
of the nucleotide-binding domain leucine-rich repeat–contain-
ing (NLR) family are key components of the inflammasome and 
interact with apoptosis-associated adaptor protein (ASC), which 
recruits the precursor form of caspase-1 (7, 8). The NLRP3 (also 
known as cryopyrin or NALP3) inflammasome is unique in its abil-
ity to recognize molecular patterns associated with host-derived 
metabolites, such as glucose or saturated fatty acids (9–13). Recent 
studies from our laboratory and others demonstrate that mitochon-
drial dysfunction involving increased mitochondrial ROS produc-
tion (12, 13) and the release of mitochondrial DNA into the cytosol 
(14) are critical events associated with NLRP3 inflammasome acti-
vation. However, recent studies have also suggested that NLRP3 
inflammasome activation may occur independently of mitochon-
drial damage and ROS production, a finding which warrants fur-
ther investigation (15, 16). The integration of metabolic derange-
ments, mitochondrial dysfunction, and inflammasome activation 
and their contribution to the pathogenesis of sepsis thus remain 
incompletely understood.
We hypothesized that metabolic regulation by mitochondria 
may represent a critical determinant of the pathogenesis of sep-
sis. We therefore sought to study the effect of metabolic regula-
tion on inflammatory responses by modulating the expression of 
mitochondrial uncoupling proteins (UCPs), a superfamily of mito-
chondrial anion carrier proteins with previously identified roles 
in metabolic regulation (17–20). UCPs uncouple oxidative phos-
Cellular lipid metabolism has been linked to immune responses; however, the precise mechanisms by which de novo fatty 
acid synthesis can regulate inflammatory responses remain unclear. The NLRP3 inflammasome serves as a platform for 
caspase-1–dependent maturation and secretion of proinflammatory cytokines. Here, we demonstrated that the mitochondrial 
uncoupling protein-2 (UCP2) regulates NLRP3-mediated caspase-1 activation through the stimulation of lipid synthesis 
in macrophages. UCP2-deficient mice displayed improved survival in a mouse model of polymicrobial sepsis. Moreover, 
UCP2 expression was increased in human sepsis. Consistently, UCP2-deficient mice displayed impaired lipid synthesis 
and decreased production of IL-1β and IL-18 in response to LPS challenge. In macrophages, UCP2 deficiency suppressed 
NLRP3-mediated caspase-1 activation and NLRP3 expression associated with inhibition of lipid synthesis. In UCP2-deficient 
macrophages, inhibition of lipid synthesis resulted from the downregulation of fatty acid synthase (FASN), a key regulator 
of fatty acid synthesis. FASN inhibition by shRNA and treatment with the chemical inhibitors C75 and cerulenin suppressed 
NLRP3-mediated caspase-1 activation and inhibited NLRP3 and pro–IL-1β gene expression in macrophages. In conclusion, 
our results suggest that UCP2 regulates the NLRP3 inflammasome by inducing the lipid synthesis pathway in macrophages. 
These results identify UCP2 as a potential therapeutic target in inflammatory diseases such as sepsis.
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strated in various cells in which UCP2 is highly expressed (23–28). 
Moreover, UCP2 affects the metabolic response to fasting in mice 
by regulating the expression of lipid regulatory enzymes and 
transcription factors (29). These observations suggest that UCP2 
exerts a central role in cellular metabolism.
Among the metabolic processes potentially influenced by 
mitochondrial dysfunction, de novo fatty acid synthesis is tightly 
regulated by key enzymes, including fatty acid synthase (FASN) 
(30). FASN and related enzymes are found upregulated in many 
cancer cells and associated with oncogenic progression (31–34). 
phorylation from ATP synthesis with energy dissipated as heat, a 
process referred to as the mitochondrial proton leak (17–20). Of 
these, UCP1 was originally identified as a protein responsible for 
thermogenesis in brown adipose tissue; whereas UCP2, its cellular 
homolog, with weak uncoupling activity, appears predominantly 
in cells of the innate immune system (17, 18). Although the physio-
logical function of UCP2 remains incompletely understood, a role 
for UCP2 in regulating cellular energy homeostasis and glucose 
metabolism has been demonstrated in various cell types (21–29). 
Modulation of the glycolytic phenotype by UCP2 has been demon-
Figure 1. Deficiency of UCP2 protects against CLP-induced mortality in vivo. (A) Immunoblot analysis of UCP2 and voltage-dependent anion channel 
(VDAC) in lung tissues from wild-type mice 8 and 24 hours after CLP or sham laparotomy. β-Actin served as the standard. *P < 0.05, ANOVA. (B) ELISA 
assay for IL-1β, IL-18, and TNF in the sera and (C) in the lung tissues from Ucp2+/+ or Ucp2–/– mice 24 hours after CLP or sham laparotomy. For both Ucp2+/+ 
and Ucp2–/– mice, sham, n = 2, and CLP, n = 8. *P < 0.05, **P < 0.01, ANOVA. (D) Organ dysfunction of CLP was determined in Ucp2+/+ or Ucp2–/– mice 24 
hours after CLP or sham laparotomy. Organ dysfunction biomarkers, including creatinine, aspartate aminotransferase (AST), and alanine aminotransferase 
(ALT), were measured in sera. For both Ucp2+/+ and Ucp2–/– mice, sham, n = 2, and CLP, n = 8. *P < 0.05, ANOVA. (E) Survival curve of CLP was determined 
in Ucp2+/+ or Ucp2–/– mice. Ucp2+/+, n = 16; Ucp2–/–, n = 29. ***P < 0.0055, log-rank test. (F) Box plots comparing measures of UCP2 mRNA levels in whole-
blood samples of sepsis (n = 30) and control (n = 19) patients. The UCP2 mRNA levels are presented as median value (black line), interquartile range (box), 
and minimum and maximum of all data (whiskers). *P < 0.05, ANOVA.
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Activation of FASN can promote glu-
cose-dependent fatty acid synthesis, 
illustrating that glucose utilization is 
coregulated with lipogenesis (30, 33, 
35). Recent studies suggest that cellu-
lar fatty acid synthesis (e.g., synthesis 
of triglycerides [TGs] and cholesteryl 
esters) is activated during inflam-
mation (36–38). Fatty acid synthesis 
has also been implicated in the acti-
vation of dendritic cells (39) and the 
differentiation of B lymphocytes and 
human monocytes (40, 41). Obesity- 
induced danger signals, such as free 
fatty acids, can activate the NLRP3 
inflammasome and the downstream 
production of IL-1β in adipose tissue 
of patients with type 2 diabetes and in 
mice fed with a high-fat diet (42, 43). 
The role of cellular fatty acid synthesis 
in macrophages during inflammation 
currently remains unclear. We hypo-
thesized that upregulation of FASN- 
dependent lipid synthesis by UCP2 reg-
ulates inflammation in sepsis through 
NLRP3 inflammasome activation.
In the current study, we show 
that UCP2-deficient mice displayed 
improved survival in a mouse model 
of polymicrobial sepsis and that 
UCP2 expression was increased in 
human sepsis. Consistent with these 
results, UCP2-deficient mice dis-
played reduced lipid synthesis and 
production of IL-1β and IL-18 in vivo 
and in vitro. Importantly, we demon-
Figure 2. Deficiency of UCP2 inhibits 
lipid production through glucose uptake 
in vivo. (A) TG production in the lungs, 
livers, and sera from LysM-Cre/Ucp2+/+ 
or LysM-Cre/Ucp2fl/fl mice after injec-
tion of LPS for 4 hours (10 mg/kg, i.p.). 
n = 3 per group, *P < 0.05, ANOVA. (B) 
Transverse SUV of PET/CT imaging using 
18F-FDG of lungs from LysM-Cre/Ucp2+/+ or 
LysM-Cre/Ucp2fl/fl mice after injection of 
LPS for 4 hours (10 mg/kg, i.p.). Represen-
tative image of 3 independent experiments. 
Original magnification, ×2. (C) Quantifica-
tion of transverse SUV in PET/CT imaging 
from B. n = 3 per group, **P < 0.01, ANOVA. 
(D) Ex vivo γ-ray counting using 18F-FDG 
of lungs and livers from LysM-Cre/Ucp2+/+ 
or LysM-Cre/Ucp2fl/fl mice after injection 
of LPS (10 mg/kg, i.p.) for 4 hours. n = 3 
per group, **P < 0.01 ANOVA. (E) Luminex 
assay and ELISA assay for IL-1β, IL-18, and 
TNF secretion in the serum from B and D.  
n = 6 per group, *P < 0.05, ANOVA.
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(Figure 1A). To evaluate the role of UCP2 in the inflammatory 
response to CLP, we analyzed the serum levels of the proinflam-
matory cytokines IL-1β, IL-18, and TNF in Ucp2+/+ and Ucp2–/– mice 
24 hours after CLP relative to those in the corresponding control 
mice subjected to sham surgery. The serum levels of IL-1β, IL-18, 
and TNF were markedly elevated in Ucp2+/+ mice after CLP com-
pared with those in sham-operated control mice. In contrast, the 
serum levels of IL-1β and IL-18 were significantly decreased in 
Ucp2–/– mice after CLP relative to those in Ucp2+/+ mice, whereas 
TNF levels were comparable between Ucp2+/+ and Ucp2–/– mice 
(Figure 1B). Similar to serum levels, the levels of IL-1β and IL-18 
in lung tissues after CLP were significantly decreased in Ucp2–/– 
mice compared with those in Ucp2+/+ mice, whereas TNF levels 
were comparable between Ucp2+/+ and Ucp2–/– mice (Figure 1C). 
We also analyzed organ dysfunction by measurement of biochem-
ical indicators of organ function in the serum. We observed that 
the levels of creatinine (an indicator of renal dysfunction) and 
aspartate aminotransferase and alanine aminotransferase (indi-
cators of hepatic dysfunction) were increased in Ucp2+/+ mice after 
CLP compared with those in sham-operated control mice. Con-
sistent with cytokine levels, Ucp2–/– mice displayed reduced organ 
strated that UCP2 regulates NLRP3 inflammasome–mediated 
caspase-1 activation by upregulating FASN-dependent lipid syn-
thesis in macrophages. The pharmacologic and genetic inhibition 
of FASN suppressed NLRP3-mediated caspase-1 activation by 
downregulation of NLRP3 and IL-1β expression. Our results sug-
gest that UCP2 is a propathogenic mediator in sepsis, whereby 
UCP2 regulates NLRP3-mediated caspase-1 activation through 
lipid synthesis (see Supplemental Figure 1 for a summary of the 
overall study; supplemental material available online with this 
article; doi:10.1172/JCI78253DS1).
Results
UCP2 promotes mortality in experimental sepsis and is upregulated 
in human sepsis. We first investigated the functional role of UCP2 
in the inflammatory response using cecal ligation and puncture 
(CLP), a clinically relevant murine model of polymicrobial sepsis. 
The expression of UCP2 was significantly increased in the lungs of 
mice at 8 hours after CLP relative to that in sham-operated control 
mice and remained elevated for up to 24 hours after CLP. In con-
trast, the expression of voltage-dependent anion channel (VDAC), 
an outer mitochondrial membrane protein, was not changed 
Figure 3. UCP2 regulates NLRP3-mediated caspase-1 activation by NLRP3 and IL-1β induction in macrophages. (A) Immunoblot analysis for caspase-1 
and IL-1β of cell lysates from Ucp2+/+ or Ucp2–/– BMDMs treated with LPS (500 ng/ml) for 4 hours, followed by incubation with ATP (2 mM) for 30 minutes. 
β-Actin served as the standard. (B) Luminex assay and ELISA assay for IL-1β, IL-18, and TNF secretion in the media from A. **P < 0.01, ANOVA. (C) ELISA 
assay for IL-1β, IL-18, and TNF secretion in the supernatants from Ucp2+/+ or Ucp2–/– BMDMs treated with LPS (500 ng/ml) for 4 hours, followed by incuba-
tion with ATP (2 mM) for 30 minutes or silica (200 mg/ml) for 10 hours. **P < 0.01, ANOVA. (D) Immunoblot analysis for Myc-tagged UCP2 and caspase-1 
of cell lysates from mouse J774A.1 macrophages transfected with control vector or Myc-tagged UCP2 expression vector, treated with LPS (500 ng/ml) for  
4 hours, followed by followed by incubation with ATP (5 mM) for 30 minutes. β-Actin served as the standard. (E) ELISA assay for IL-1β, IL-18, and TNF secre-
tion in the supernatants from mouse J774A.1 macrophages transfected with control vector or Myc-tagged UCP2 expression vector, treated with LPS  
(500 ng/ml) for 4 hours, followed by incubation with ATP (5 mM) for 30 minutes. *P < 0.05, ANOVA.
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cantly decreased in LysM-Cre/Ucp2fl/fl mice 
relative to those in LysM-Cre/Ucp2+/+ mice 
(Figure 2A). Next, to confirm that LPS- 
induced TG synthesis was associated with 
glucose utilization, we measured glucose 
uptake using 18F-fluoro-2-deoxyglucose 
(18F-FDG) in mice treated with LPS. The 
uptake of 18F-FDG in mouse organs was 
measured using positron emission tomog-
raphy/computerized tomography (PET/
CT) imaging and ex vivo γ-ray counting 
in tissue sections of LysM-Cre/Ucp2+/+ 
and LysM-Cre/Ucp2fl/fl mice. The uptake 
of 18F-FDG in mouse organs was imaged 
using a micro-PET scanner for 20 minutes, 
and then the anatomical localization of the 
lung and liver was imaged using a CT scan-
ner. The analysis of 18F-FDG uptake was 
performed using a combination of whole-
body CT images and standard uptake val-
ues (SUVs) from PET imaging. Consistent 
with the observed increases in TG synthe-
sis, LPS treatment increased the uptake of 
18F-FDG in LysM-Cre/Ucp2+/+ mice 4 hours 
after LPS injection, as detected in trans-
verse PET/CT imaging of the lungs. In contrast, the lung uptake 
of 18F-FDG in LysM-Cre/Ucp2fl/fl mice was decreased compared 
with that in LysM-Cre/Ucp2+/+ mice (Figure 2, B and C). In cor-
onal PET/CT imaging, the uptake of 18F-FDG was reduced in 
the lungs and livers in LysM-Cre/Ucp2fl/fl mice relative to that in 
LysM-Cre/Ucp2+/+ mice after LPS treatment (Supplemental Fig-
ure 2). To confirm the results of PET/CT imaging, we measured 
the uptake of 18F-FDG in tissue sections using ex vivo γ-ray count-
ing. Consistent with results observed in PET/CT imaging, ex vivo 
γ-ray counting revealed increased uptake of 18F-FDG in the lungs 
and livers of LysM-Cre/Ucp2+/+ mice after LPS treatment (Figure 
2D). The levels of glucose uptake in LysM-Cre/Ucp2fl/fl mice were 
decreased in the lungs and livers after LPS treatment compared 
with those in LysM-Cre/Ucp2+/+ mice (Figure 2D). These results 
indicate that UCP2 regulates lipid synthesis, which is correlated 
with glucose utilization in tissues in response to LPS challenge 
in vivo. Next, we investigated whether lipid synthesis was asso-
ciated with serum levels of IL-1β and IL-18 in LysM-Cre/Ucp2+/+ 
mice. Consistent with reduced TG levels and glucose utilization, 
the serum levels of IL-1β and IL-18 were significantly suppressed 
in LysM-Cre/Ucp2fl/fl mice relative to those in LysM-Cre/Ucp2+/+ 
mice, whereas TNF production was unchanged (Figure 2E). 
These results suggest that UCP2 regulates de novo lipid synthesis, 
which was associated with glucose utilization and the production 
of IL-1β and IL-18 in vivo.
UCP2 regulates NLRP3 expression and caspase-1 activation 
in macrophages. UCP2 deficiency and corresponding metabolic 
changes were associated with altered regulation of inflammasom-
e-associated cytokines in vivo. Therefore, we investigated whether 
UCP2 regulates the production of IL-1β and IL-18 in macrophages 
through NLRP3-dependent caspase-1 activation. We used an 
established model of NLRP3 inflammasome–mediated caspase-1 
dysfunction relative to Ucp2+/+ mice (Figure 1D). Importantly, we 
observed that Ucp2–/– mice were more resistant to CLP-induced 
mortality than Ucp2+/+ mice. At 7 days after CLP, 75% of Ucp2+/+ 
mice had died, whereas 70% of Ucp2–/– mice survived longer than 
12 days (Figure 1E). These results demonstrate improved survival 
of Ucp2–/– mice in the CLP model. Next, to correlate our findings in 
mice to patients with sepsis, we analyzed the mRNA level of UCP2 
in leukocytes from patients admitted to the MICU. We observed 
that UCP2 mRNA levels of leukocytes from the whole blood of 
patients with sepsis were significantly increased (P = 0.029) com-
pared with those of control patients admitted to the MICU without 
sepsis (see Methods for selection criteria, Figure 1F and Supple-
mental Table 1). Taken together, these results suggest that UCP2 is 
a critical mediator in the pathogenesis of sepsis.
UCP2 deficiency suppresses lipid synthesis and cytokine produc-
tion in vivo. The accumulation of lipid metabolites has been asso-
ciated with systemic inflammation in mice and humans (37, 38). 
Moreover, alterations in glucose metabolism, including glucose 
consumption and glycolysis, have been linked to cytokine produc-
tion in immune cells (7, 9, 39). We investigated whether UCP2 can 
act as a critical regulator of cellular metabolism as it relates to the 
activation of inflammation. Since UCP2 functions in cellular met-
abolic regulation (25–28), we investigated whether UCP2 can reg-
ulate lipid synthesis in response to LPS challenge in vivo. We first 
measured the levels of TGs, a final product in the lipid synthesis 
pathway, in the lung and liver tissues of mice with a myeloid cell–
specific deletion of UCP2 (LysM-Cre/Ucp2fl/fl mice) in response 
to LPS challenge. LPS treatment increased TG levels in the lungs 
and livers of LysM-Cre/Ucp2+/+ mice (Figure 2A). Consistent with 
elevated TG levels in tissues, LPS treatment also increased TG 
levels in the sera of LysM-Cre/Ucp2+/+ mice (Figure 2A). In con-
trast, the levels of TGs in the lungs, livers, and sera were signifi-
Figure 4. UCP2 regulates lipid synthesis via FASN in macrophages. (A) TGs in Ucp2+/+ or Ucp2–/– 
BMDMs treated with LPS (500 ng/ml) for 4 hours. *P < 0.05, ANOVA. (B) 18F-FDG uptake and PEP and 
lactate production in Ucp2+/+ or Ucp2–/– BMDMs treated with LPS (500 ng/ml) for 4 hours. *P < 0.05, 
ANOVA. (C) Citrate production in Ucp2+/+ or Ucp2–/– BMDMs treated with LPS (500 ng/ml) for 4 hours. 
*P < 0.05, ANOVA. (D) Immunoblot analysis for FASN, ACACA, and ACLY in cell lysates from Ucp2+/+ or 
Ucp2–/– BMDMs treated with LPS (500 ng/ml) for 4 hours. β-Actin served as the standard.
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activation in vitro, the stimulation of LPS-primed macrophages 
with ATP treatment. We analyzed caspase-1 activation in bone 
marrow–derived macrophages (BMDMs) isolated from Ucp2–/– 
mice or corresponding wild-type (Ucp2+/+) mice. Ucp2–/– BMDMs 
displayed reduced expression of cleaved caspase-1 and cleaved 
IL-1β in response to LPS and ATP, relative to Ucp2+/+ BMDMs (Fig-
ure 3A). Ucp2–/– BMDMs displayed reduced protein induction of 
pro–IL-1β in response to LPS. Importantly, Ucp2–/– BMDMs also 
displayed reduced protein expression of NLRP3 in response to LPS 
compared with Ucp2+/+ BMDMs. Consistent with protein levels, 
UCP2 deficiency significantly reduced Nlrp3 gene expression (Sup-
plemental Figure 3). In contrast to NLRP3, the expression of ASC 
and pro–caspase-1 was unchanged in Ucp2–/– BMDMs (Figure 3A). 
Moreover, IL-1β and IL-18 secretion was significantly decreased in 
Ucp2–/– BMDMs relative to that in Ucp2+/+ BMDMs, while TNF secre-
tion was comparable in both Ucp2+/+ and Ucp2–/– BMDMs (Figure 
3B). Additionally, we tested the role of UCP2 in modulating inflam-
masome responses to other stimuli. Ucp2–/– BMDMs displayed 
reduced IL-1β and IL-18 secretion in response to treatment with 
silica, an alternative NLRP3 inflammasome activator, relative to 
Ucp2+/+ BMDMs, while the secretion of TNF was comparable in both 
Ucp2+/+ and Ucp2–/– BMDMs (Figure 3C). Next, we overexpressed 
UCP2 in J774A.1 macrophages and validated the expression levels 
by Western immunoblot analysis (Figure 3D). Overexpression of 
UCP2 in J774A.1 macrophages increased caspase-1 activation in 
response to LPS and ATP compared with control-transfected cells 
(Figure 3D). Moreover, overexpression of UCP2 increased IL-1β 
and IL-18 secretion in response to LPS and ATP, while the secretion 
of TNF was not changed (Figure 3E). Next, we analyzed whether 
UCP2 can regulate caspase-1 activation in response to LPS and 
poly(dA:dT) treatment, which activates the absent in melanoma 
2 (AIM2) inflammasome pathway. Unlike NLRP3-mediated cas-
pase-1 activation in Ucp2–/– BMDMs, the expression of AIM2 and 
cleaved caspase-1 was unchanged in Ucp2–/– and Ucp2+/+ BMDMs in 
response to LPS and poly(dA:dT) treatment (Supplemental Figure 
4), suggesting that the AIM2 inflammasome pathway is not regu-
lated by UCP2. Overall, our results suggest that UCP2 regulates 
NLRP3-mediated caspase-1 activation as well as the production of 
NLRP3 and pro–IL-1β in macrophages.
UCP2 regulates glucose utilization and de novo lipid synthesis 
in macrophages. UCP2 deficiency was associated with metabolic 
changes in vivo, including reduced glucose utilization and TG 
synthesis (Figure 2). De novo fatty acid synthesis is known to 
require glucose (30, 32–34). We next evaluated the role of UCP2 
in de novo lipid synthesis and associated changes in glucose 
metabolism in vitro. We first measured TG synthesis in BMDMs 
isolated from Ucp2–/– or Ucp2+/+ mice. Similar to reduced TG levels 
observed in the lungs, livers, and sera of Ucp2–/– mice (Figure 2A), 
Ucp2–/– BMDMs displayed less TG synthesis in response to LPS 
relative to that of Ucp2+/+ BMDMs (Figure 4A). Next, to examine 
whether LPS-induced TG synthesis was associated with glucose 
utilization in vitro, we measured glucose utilization using 18F-FDG 
and the production of glycolytic metabolites in Ucp2–/– BMDMs in 
response to LPS. Consistent with reduced TG synthesis, Ucp2–/– 
BMDMs displayed less 18F-FDG uptake compared with Ucp2+/+ 
BMDMs (Figure 4B). Furthermore, the production of phosphoe-
nolpyruvate (PEP) and lactate (Figure 4B) and citrate (Figure 4C), 
representative metabolites in glycolysis and the tricarboxylic acid 
cycle, respectively, was significantly suppressed in Ucp2–/– BMDMs 
relative to that in Ucp2+/+ BMDMs. Similar to results obtained in 
BMDMs, TG synthesis (Supplemental Figure 5A) and the produc-
tion of PEP, lactate, and citrate (Supplemental Figure 5, B and C) 
were significantly suppressed in Ucp2–/– peritoneal macrophages in 
response to LPS compared with Ucp2+/+ peritoneal macrophages.
Figure 5. FASN regulates NLRP3 and IL-1β expression in macrophages. (A) Immunoblot analysis for FASN, NLRP3, and IL-1β in cell lysates from wild-type 
mouse peritoneal macrophages transduced with lentiviruses expressing nontarget shRNA (Control shRNA) or 3 independent shRNA for FASN (shFASN 
#1, #2, and #3) and stimulated with LPS (500 ng/ml) for 4 hours. β-Actin served as the standard. (B) TG production and (C) PEP, citrate, and lactate 
production in wild-type mouse peritoneal macrophages transduced with lentiviruses expressing nontarget shRNA or 3 independent shRNA for FASN and 
stimulated with LPS (500 ng/ml) for 4 hours. *P < 0.05, ANOVA.
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Although glucose utilization and production of glycolytic 
metabolites was suppressed in Ucp2–/– BMDMs compared with 
that in Ucp2+/+ BMDMs, the expression of the glucose trans-
porter-1 (GLUT1) was comparable between Ucp2–/– and Ucp2+/+ 
BMDMs (Supplemental Figure 6). These results suggest that 
UCP2 regulates de novo lipid synthesis in macrophages through 
modulation of glycolysis.
UCP2 regulates lipid synthesis through FASN in macrophages. 
We next investigated the molecular mechanism by which lipid 
synthesis is regulated by UCP2 in macrophages. Since UCP2 
can regulate the lipid metabolic response to fasting in mice 
through the expression of key lipid regulatory enzymes (29, 
33), we analyzed whether UCP2 regulates lipogenic enzymes in 
the lipid synthesis pathway in macrophages. Lipid synthesis is 
regulated by the expression of key lipogenic enzymes, includ-
ing FASN, acetyl-CoA carboxylase (ACACA), and ATP citrate 
lyase (ACLY). We analyzed the expression of FASN, ACACA, 
and ACLY in Ucp2–/– BMDMs in response to LPS. The expression 
of FASN, ACACA, and ACLY was increased in Ucp2+/+ BMDMs 
in response to LPS (Figure 4D). In contrast, Ucp2–/– BMDMs 
displayed markedly reduced FASN induction compared with 
Ucp2+/+ BMDMs, while the expression of ACACA was partially 
reduced and the expression of ACLY was unchanged (Figure 
4D). Consistent with results obtained in BMDMs, the induction 
of FASN was markedly suppressed in Ucp2–/– peritoneal macro-
phages in response to LPS relative to Ucp2+/+ peritoneal macro-
phages (Supplemental Figure 5D). These results suggest that 
UCP2 regulates lipid synthesis via FASN in macrophages.
FASN regulates NLRP3 expression in macrophages. FASN, a 
critical lipogenic enzyme that promotes glucose-dependent fatty 
acid synthesis (30, 33, 35), was preferentially downregulated in 
Ucp2–/– BMDMs and peritoneal macrophages, in association with 
inhibition of the inflammatory response. We therefore sought to 
investigate the role of FASN in NLRP3 regulation in macrophages. 
We analyzed whether deficiency of FASN could suppress NLRP3 
expression in response to proinflammatory stimuli. Genetic dele-
tion of FASN results in early embryonic lethality (44), preclud-
ing the use of Fasn–/– mice in the current study. Hence, we used 
3 independent shRNA lentiviral constructs against mouse Fasn 
to knockdown FASN in wild-type peritoneal macrophages. The 
protein expression of NLRP3 in response to LPS stimulation was 
suppressed by Fasn shRNA transduction relative to control shRNA 
transduction (Figure 5A). Moreover, knockdown of FASN sup-
pressed the protein expression of pro–IL-1β (Figure 5A). Consis-
tent with the results observed in Ucp2–/– BMDMs, knockdown of 
FASN significantly suppressed the production of TGs compared 
with control (Figure 5B). Similarly, knockdown of FASN reduced 
the production of PEP, citrate, and lactate in response to LPS rel-
ative to control, as previously reported (ref. 31 and Figure 5C). 
Consistent with the results in peritoneal macrophages, the protein 
Figure 6. FASN regulates NLRP3 and IL-1β 
expression through AKT activation in 
macrophages. (A) Immunoblot analysis 
for NLRP3 and IL-1β and (B) measurement 
of TGs from wild-type BMDMs pretreated 
with C75 (0, 10, 20, and 50 μM) as well 
as (C) measurement of PEP, citrate, and 
lactate production from wild-type BMDMs 
pretreated with C75 (20 μM) for 2 hours 
before stimulation with LPS (500 ng/ml, 
4 hours). β-Actin served as the standard. 
**P < 0.01, ANOVA. (D) Immunoblot 
analysis of AKT Ser473 phosphorylation in 
wild-type BMDMs pretreated with C75  
(20 μM) for 2 hours before stimulation 
with LPS (500 ng/ml; 0, 10, and 20 min-
utes). Total AKT served as the standard. 
(E) Immunoblot analysis of AKT Ser473 
phosphorylation in cell lysates from 
wild-type BMDMs pretreated with C75 
(0, 10, 20, and 50 μM) for 2 hours before 
stimulation with LPS (500 ng/ml, 4 
hours). Total AKT served as the standard. 
(F) Immunoblot analysis of AKT Ser473 
phosphorylation in cell lysates from wild-
type peritoneal macrophages transduced 
with lentiviruses expressing nontarget 
shRNA or 3 independent shRNA for FASN 
after stimulation with LPS (500 ng/ml, 4 
hours). Total AKT served as the standard. 
(G) Immunoblot analysis for NLRP3, IL-1β, 
and AKT Ser473 phosphorylation in cell 
lysates from wild-type BMDMs pretreated 
with BX795 (10 μM) for 1 hour before stim-
ulation with LPS (500 ng/ml, 4 hours). 
Total AKT served as the standard.
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
6 7 2 jci.org   Volume 125   Number 2   February 2015
Since FASN activity is known to modulate AKT activation 
in cancer cells (45), we investigated whether inhibition of FASN 
activity by C75 can suppress NLRP3 expression through AKT in 
macrophages. First, we analyzed the phosphorylation of AKT on 
Ser473 in wild-type BMDMs treated with C75 prior to LPS stim-
ulation. C75 suppressed the phosphorylation of AKT on Ser473 
in response to LPS treatment, relative to vehicle control (Figure 
6D). Similarly, C75 suppressed the phosphorylation of AKT on 
Ser473 in a dose-dependent manner (Figure 6E). Moreover, TLR 
agonist-induced AKT activation was suppressed by C75 com-
pared with vehicle control (Supplemental Figure 8B). Consistent 
with inhibition of AKT activation by C75, knockdown of FASN 
by Fasn shRNA suppressed AKT activation relative to control 
shRNA transduction in wild-type peritoneal macrophages (Fig-
ure 6F). Similarly, cerulenin suppressed the phosphorylation of 
AKT on Ser473 in a dose-dependent manner (Supplemental Fig-
ure 9E). Consistent with Fasn shRNA transduction, knockdown 
of FASN by Fasn-specific siRNA suppressed AKT activation rela-
tive to control siRNA transfection in J774A.1 macrophages (Sup-
plemental Figure 9F).
Next, to evaluate the role of AKT activation in the regulation 
of NLRP3 expression, we examined whether inhibition of AKT by 
BX795, a selective AKT inhibitor, could suppress NLRP3 expres-
sion in macrophages in response to LPS (Figure 6G). Pretreatment 
of BMDMs with BX795 prior to LPS stimulation resulted in reduced 
NLRP3 expression in response to LPS. Moreover, BX795 also sup-
pressed the protein expression of pro–IL-1β and phosphorylation of 
AKT on Ser473 in response to LPS (Figure 6G). These results sug-
gest that FASN regulates NLRP3 expression via AKT activation.
FASN regulates the transcription of NLRP3 and IL-1β in macro-
phages through p38 MAPK. We investigated the molecular mecha-
nism by which the induction of NLRP3 and pro–IL-1β is regulated 
by FASN in macrophages. Since AKT signaling is involved in the 
regulation of NLRP3 by FASN (Figure 6), we examined whether 
expression of NLRP3 and pro–IL-1β in response to LPS stimulation 
was suppressed by Fasn-specific siRNA transfection relative to con-
trol siRNA transfection in J774A.1 macrophages. The production 
of TG, PEP, citrate, and lactate in response to LPS was reduced by 
FASN knockdown in J774A.1 macrophages (Supplemental Figure 
7). These results support that FASN promotes glucose-dependent 
lipid synthesis in macrophages. Taken together, these results sug-
gest that FASN regulates NLRP3 expression in macrophages.
FASN activity regulates NLRP3 expression via AKT activation in 
macrophages. To validate the functional role of FASN in the regu-
lation of NLRP3 expression, we examined whether inhibition of 
FASN activity by C75, a selective inhibitor of FASN (31, 33), could 
inhibit the expression of NLRP3 in macrophages in response to LPS. 
We analyzed the protein induction of NLRP3 in wild-type BMDMs 
treated with C75. Pretreatment with C75 dose dependently sup-
pressed the protein expression of NLRP3 and pro–IL-1β in wild-
type BMDMs in response to LPS (Figure 6A). Consistent with 
FASN downregulation, C75 dose dependently reduced TG synthe-
sis in wild-type BMDMs (Figure 6B). Similarly, C75 suppressed the 
production of PEP, citrate, and lactate in response to LPS relative to 
vehicle control (Figure 6C). Furthermore, C75 suppressed NLRP3 
and pro–IL-1β expression in wild-type BMDMs after stimulation 
with alternate TLR ligands (Supplemental Figure 8A). Consistent 
with the results in wild-type BMDMs, C75 dose dependently sup-
pressed the protein expression of NLRP3 and pro–IL-1β in wild-
type peritoneal macrophages in response to LPS compared with 
vehicle control (Supplemental Figure 9A). Consistent with C75 
treatment, cerulenin, another selective inhibitor of FASN (31, 33), 
dose dependently suppressed the protein expression of NLRP3 and 
pro–IL-1β in wild-type peritoneal macrophages in response to LPS 
compared with vehicle control (Supplemental Figure 9B). Similar 
to C75 treatment, cerulenin significantly suppressed TG synthesis 
and the production of PEP, citrate, and lactate in response to LPS 
relative to vehicle control (Supplemental Figure 9, C and D).
Figure 7. Deficiency of FASN suppresses the transcription of Nlrp3 and Il1b genes through p38 MAPK in macrophages. (A) Quantitative PCR analysis 
for Nlrp3, Il1b, Il18, Tnf, and Il12 gene expression in wild-type mouse peritoneal macrophages transduced with lentiviruses expressing nontarget shRNA 
or shRNA for FASN (shFASN) and stimulated with LPS (500 ng/ml) for 4 hours. **P < 0.01, ANOVA. (B) Immunoblot analysis for activation of p38 MAPK, 
ERK, and JNK in cell lysates from wild-type mouse peritoneal macrophages transduced with control shRNA or shRNA for FASN and stimulated with LPS 
(500 ng/ml) for 0, 10, 20, and 30 minutes.
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p38α MAPK in wild-type 
peritoneal macrophages. 
The activation of p38 
MAPK in response to LPS 
and p38 MAPK expres-
sion was markedly sup-
pressed by p38α shRNA 
compared with control 
shRNA transduction in 
wild-type peritoneal mac-
rophages (Figure 8A). 
Consistent with knock-
down of FASN, transduc-
tion with p38α shRNA 
markedly reduced the 
protein expression of 
NLRP3 and pro–IL-1β 
relative to control shRNA 
transduction (Figure 8B). 
Next, to examine the role 
of p38 MAPK in the gene 
expression of NLRP3 
and pro–IL-1β, we ana-
lyzed the mRNA levels 
of Nlrp3, Il1b, and Il18 
in wild-type peritoneal 
macrophages. Similar to protein expression, knockdown of p38 
MAPK markedly reduced Nlrp3, Il1b, and Il18 gene expression in 
response to LPS compared with control shRNA transduction (Fig-
ure 8C). Unlike Il1b and Il18 gene expression, gene expression of 
Tnf was significantly reduced by knockdown of p38 MAPK during 
the early response to LPS stimulation, whereas it was comparable 
with control conditions at 4 hours after LPS stimulation (Supple-
mental Figure 12, A and B). In contrast, gene expression of Il12 was 
unchanged by knockdown of p38 MAPK (Supplemental Figure 
12B). Moreover, we evaluated the role of LPS-induced p38 MAPK 
activation in the transcription of NLRP3, pro–IL-1β, and other 
cytokine genes. We analyzed the mRNA levels of Nlrp3, Il1b, Il18, 
and Tnf in wild-type BMDMs using LPS in the absence or presence 
of SB203580, a potent inhibitor of p38 MAPK activation; U0126, a 
potent inhibitor of ERK activation; and SP600125, a potent inhib-
itor of JNK activation. SB203580 significantly suppressed Nlrp3, 
Il1b, and Il18 gene expression in response to LPS compared with 
vehicle control, while gene expression of Tnf was unchanged. In 
contrast, U0126 partially suppressed Il1b gene expression relative 
to vehicle control, while Nlrp3, Il18, and Tnf mRNA levels were 
unchanged. SP600125 did not affect the transcription of Nlrp3, 
Il1b, Il18, and Tnf genes in response to LPS compared with vehi-
cle control (Figure 9A). Consistent with mRNA levels, SB203580 
markedly suppressed the protein expression of NLRP3 and pro–
IL-1β (Figure 9B). In contrast, U0126 partially reduced protein 
expression of pro–IL-1β, while that of NLRP3 was comparable. 
SP600125 did not inhibit the protein expression of NLRP3 and 
pro–IL-1β (Figure 9B). These results suggest that FASN regulates 
the transcription of NLRP3 through the p38 MAPK signaling path-
way and FASN regulates the transcription of pro–IL-1β through the 
p38 MAPK and ERK1/2 MAPK signaling pathway in macrophages.
deficiency of FASN can regulate the expression of NLRP3 and 
pro–IL-1β through AKT-dependent transcription in macrophages. 
We first analyzed the mRNA levels of Nlrp3, Il1b, Il18, Tnf, and Il12 
in wild-type peritoneal macrophages in response to LPS. Trans-
duction with Fasn shRNA markedly reduced Nlrp3, Il1b, and Il18 
gene expression in response to LPS compared with control shRNA 
transduction, while gene expression of Tnf and Il12 was unchanged 
(Figure 7A). Similar to transduction with Fasn shRNA, knockdown 
of FASN by Fasn-specific siRNA markedly reduced Nlrp3, Il1b, 
and Il18 gene expression in response to LPS compared with con-
trol siRNA transfection in J774A.1 macrophages, while Tnf gene 
expression was unchanged (Supplemental Figure 10A).
Next, to examine whether deficiency of FASN can affect sig-
naling pathways downstream of AKT, we analyzed the effects 
of FASN knockdown on the activation of MAPKs, including p38 
MAPK, ERK, and JNK in wild-type peritoneal macrophages. Fasn 
shRNA transduction suppressed the activation of p38 MAPK 
and ERK relative to control shRNA, while the activation of JNK 
was unchanged (Figure 7B). Similarly, knockdown of FASN by 
Fasn-specific siRNA markedly suppressed the activation of p38 
MAPK compared with control siRNA transfection in J774A.1 
macrophages (Supplemental Figure 10B). Consistent with FASN 
knockdown, inhibition of AKT by BX795 treatment suppressed 
the activation of p38 MAPK compared with vehicle control (Sup-
plemental Figure 11). Since the activation of p38 MAPK was mark-
edly suppressed by FASN knockdown (Figure 7B), we analyzed the 
role of p38 MAPK in the transcription of NLRP3 and pro–IL-1β in 
wild-type peritoneal macrophages.
Since the p38α isoform, among the p38 MAPK isoforms, is the 
most abundant in inflammatory cells (46), we used 2 independent 
shRNA lentiviral constructs against mouse p38α to knockdown 
Figure 8. p38 MAPK regulates NLRP3 and IL-1β expression in macrophages. (A) Immunoblot analysis for activation of 
p38 MAPK in cell lysates from wild-type mouse peritoneal macrophages transduced with lentiviruses expressing non-
target shRNA or 2 independent shRNA for p38 (shp38 #1 and #2) and stimulated with LPS (500 ng/ml) for 0, 10, or 20 
minutes. β-Actin served as the standard. (B) Immunoblot analysis for expression of NLRP3 and IL-1β in cell lysates from 
wild-type mouse peritoneal macrophages transduced with lentiviruses expressing control shRNA or 2 independent shRNA 
for p38 and stimulated with LPS (500 ng/ml) for 4 hours. β-Actin served as the standard. (C) Quantitative PCR analysis for 
Nlrp3, Il1b, and Il18 gene expression in wild-type mouse peritoneal macrophages transduced with lentiviruses expressing 
control shRNA or shRNA for p38 (shp38) and stimulated with LPS (500 ng/ml) for 4 hours. **P < 0.01, ANOVA.
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in response to LPS relative to vehicle control in wild-type BMDMs 
(Supplemental Figure 13C). Moreover, IL-1β and IL-18 secretion was 
also significantly decreased by C75 in response to LPS and ATP rela-
tive to vehicle control (Supplemental Figure 13D). Collectively, these 
results suggest that FASN is required for NLRP3 inflammasome–
dependent caspase-1 activation as well as IL-1β and IL-18 secretion.
Inhibition of FASN by C75 suppresses the production of IL-1β and 
IL-18 in vivo. Finally, we investigated the role of FASN activity in 
the production of IL-1β and IL-18 in vivo. We measured the sera 
levels of IL-1β and IL-18 in wild-type mice treated with C75 prior 
to LPS injection. C75 significantly reduced the sera levels of IL-1β 
and IL-18 (Figure 11A) and TGs (Figure 11B) in response to LPS, 
relative to vehicle control. Similarly, cerulenin also reduced the 
sera levels of IL-1β and IL-18 (Figure 11C) and TGs (Figure 11D) 
in response to LPS, relative to vehicle control. Consistently, LPS 
induced lipid accumulation in the liver was inhibited by C75 (Fig-
ure 11E). These results suggest that the activity of FASN is required 
for IL-1β and IL-18 production in vivo.
Discussion
In this study, we demonstrate the physiological relevance of 
the mitochondrial protein UCP2 in mediating inflammatory 
responses in two animal models of sepsis: the endotoxin shock 
model and the CLP model of polymicrobial sepsis. Furthermore, 
increased UCP2 mRNA expression was observed in the blood of 
human sepsis patients.
We have shown that UCP2 acts as a critical regulator of 
glucose-dependent de novo lipid synthesis in vivo and in vitro. 
We describe a molecular mechanism whereby FASN, a criti-
cal lipogenic enzyme that converts glycolytic carbon flux into 
lipid biosynthesis, serves as a downstream target molecule of 
UCP2-dependent glucose regulation. We show that UCP2- 
dependent lipid synthesis under the regulation of FASN is critical 
for both NLRP3-mediated caspase-1 activation and the regula-
tion of NLRP3 and pro–IL-1β expression. Similar to observations 
in UCP2-deficient mice, genetic and pharmacologic inhibition 
of FASN suppressed NLRP3-mediated caspase-1 activation and 
the synthesis of NLRP3 and pro–IL-1β in vitro as well as IL-1β 
and IL-18 production in vivo. In the current study, we describe 
a molecular mechanism by which UCP2 and FASN regulate 
the NLRP3 inflammasome and associated caspase-1 activation 
through the regulation of lipid synthesis. Our results suggest that 
UCP2- and FASN-mediated lipid synthesis is linked to inflam-
matory responses. A summary of the proposed role of UCP2 
and FASN in the regulation of metabolism and inflammation is 
shown in Figure 12 and Supplemental Figure 1.
Among the known UCPs, UCP2 is highly expressed in immune 
cells from humans and mice and has been implicated in the patho-
genesis of type 2 diabetes and obesity (18, 47). Recently, UCP2 has 
FASN regulates caspase-1 activation and associated cytokine produc-
tion in macrophages. Based on our results that FASN expression and 
activity are critical for NLRP3 expression, we therefore investigated 
the role of FASN in NLRP3-mediated caspase-1 activation in mac-
rophages. Similar to the result observed in Ucp2–/– BMDMs, FASN 
knockdown by Fasn shRNA suppressed the expression of cleaved 
caspase-1 and cleaved IL-1β in wild-type peritoneal macrophages in 
response to LPS and ATP compared with control shRNA-transduced 
cells (Figure 10A). Moreover, FASN knockdown reduced the protein 
expression of NLRP3 and pro–IL-1β in response to LPS. In contrast to 
NLRP3, the expression of ASC and caspase-1 was unchanged in Fasn 
shRNA-transduced cells (Figure 10A). IL-1β and IL-18 secretion was 
also significantly decreased in Fasn shRNA-transduced cells relative 
to control cells, while TNF secretion was comparable between cells 
(Figure 10B and Supplemental Figure 14A). Similarly, FASN knock-
down by Fasn-specific siRNA suppressed the expression of cleaved 
caspase-1 and cleaved IL-1β in mouse J774A.1 macrophages in 
response to LPS and ATP compared with control siRNA-transfected 
cells (Supplemental Figure 13A). Moreover, IL-1β and IL-18 secretion 
was also significantly decreased (Supplemental Figure 13B), while 
TNF secretion was comparable (Supplemental Figure 14B). Con-
sistent with FASN knockdown, inhibition of FASN activity by C75 
and cerulenin suppressed NLRP3-mediated caspase-1 activation in 
response to LPS and ATP relative to vehicle treatment in wild-type 
peritoneal macrophages (Figure 10C). C75 and cerulenin also sup-
pressed the protein induction of NLRP3 and pro–IL-1β in response to 
LPS, while the expression of ASC and caspase-1 was unchanged (Fig-
ure 10C). Moreover, IL-1β and IL-18 secretion was also significantly 
decreased by C75 and cerulenin treatment (Figure 10D). Similar to 
results in peritoneal macrophages, inhibition of FASN activity by 
C75 suppressed NLRP3-mediated caspase-1 activation in response 
to LPS and ATP and the protein induction of NLRP3 and pro–IL-1β 
Figure 9. Inhibition of p38 MAPK activation suppresses the transcription 
of Nlrp3 and Il1b genes in macrophages. (A) Quantitative PCR analysis for 
Nlrp3, Il1b, Il18, and Tnf gene expression in cell lysates and (B) immunoblot 
analysis for expression of NLRP3 and IL-1β in cell lysates from wild-type 
BMDMs pretreated with SB203580 (10 μM), U0126 (10 μM), and SP600125 
(10 μM) for 1 hour before stimulation with LPS (500 ng/ml) for 4 hours.  
*P < 0.05, **P < 0.01, ANOVA. β-Actin served as the standard.
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reduced TG synthesis and production of glycolytic metabolites 
as the result of FASN downregulation. Consistent with the results 
observed in Ucp2–/– cells, inhibition of FASN also suppressed the 
production of glycolytic metabolites. Glucose utilization is reg-
ulated by activation of the glucose transporter or by changes in 
glycolysis (49). GLUT1, which is the predominant glucose trans-
porter in macrophages, mediates high glucose uptake and the 
glycolytic phenotype in macrophages (50). Our results suggest 
that UCP2 affects glucose utilization independently of the reg-
ulation of GLUT1. Although the function of UCP2 in different 
tissue types remains controversial (51, 52), our results suggest 
that UCP2 has a significant impact on metabolic reprograming 
processes in macrophages.
Furthermore, our human data suggest that UCP2 expression 
was increased in myeloid cells of patients with sepsis, compared 
with patients with systemic inflammatory response syndrome, 
suggesting that UCP2 was regulated in patients with systemic 
inflammation and infection. Our prior studies demonstrate 
that changes in plasma metabolic profiles, including changes 
also been shown to be involved in numerous pathophysiological 
conditions, including metabolic disorders, inflammation, ische-
mic shock, cancer, and aging. UCP2 decreases glucose-derived 
pyruvate oxidation in mitochondria and enhances aerobic glycol-
ysis (23, 25, 26, 48). Metformin, a drug used in the treatment of 
type 2 diabetes, can induce UCP2 expression and increase glucose 
utilization in peripheral tissues (24). UCP2 mediates the shift from 
mitochondrial respiration to aerobic glycolysis (Warburg effect) as 
well as tumorigenic properties associated with cancer cells (25–
27). Furthermore, UCP2 can facilitate the transport of 4-carbon 
(C4) tricarboxylic acid cycle metabolites (e.g., malate, oxaloace-
tate) from the mitochondria to the cytosol, which supports a role 
for UCP2 in the reprograming of glucose utilization (28). These 
studies provide evidence that UCP2 has a significant regulatory 
role in cellular metabolism and bioenergetics.
Our results show that UCP2 regulates cellular glucose utiliza-
tion and glycolysis during inflammation. Furthermore, our data 
show that the UCP2-mediated glycolytic phenotype is regulated 
by FASN-dependent lipid synthesis. Ucp2–/– BMDMs displayed 
Figure 10. FASN regulates NLRP3-mediated caspase-1 activation in macrophages. (A) Immunoblot analysis for caspase-1 and IL-1β of cell lysates 
from wild-type mouse peritoneal macrophages transduced with lentiviruses expressing nontarget shRNA or shRNA for FASN and stimulated with LPS 
(500 ng/ml) for 4 hours, followed by incubation with ATP (5 mM) for 30 minutes. β-Actin served as the standard. (B) ELISA assay for IL-1β and IL-18 
in the media from A. **P < 0.01, ANOVA. (C) Immunoblot analysis for IL-1β and NLRP3 of cell lysates from wild-type mouse peritoneal macrophages 
pretreated with C75 (20 μM) and cerulenin (2 g/ml) for 2 hours before stimulation with LPS (500 ng/ml) for 4 hours, followed by incubation with ATP  
(5 mM) for 30 minutes. β-Actin served as the standard. (D) ELISA assay for IL-1β and IL-18 in the media from C. **P < 0.01, ANOVA.
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standard care (target glucose range, 180–200 
mg/dl) (57). However, most of subsequent trials 
did not confirm such a benefit, while they also 
raised the concern of hypoglycemia as a risk 
factor of death (58).
For years, NLRP3 has been exclusively 
studied as a critical component of the NLRP3 
inflammasome, which promotes the cleavage 
of caspase-1. While previous reports suggest 
that activation of NF-κB by pattern recognition 
receptors such as TLR4 is necessary for NLRP3 
expression (3), the precise molecular mechanism 
remains unclear. We show that FASN-depen-
dent lipid synthesis acts as an upstream signal 
for NLRP3 expression. Consistent with these 
results, inhibition of fatty acid synthesis by FASN 
deficiency and inhibition by C75 suppressed 
NLRP3 expression involving AKT activation in 
macrophages. FASN is a multifunctional met-
abolic enzyme that catalyzes the terminal steps 
in the synthesis of long-chain saturated fatty 
acids (33). The production of fatty acids sup-
ports membrane synthesis in proliferating cells 
(33). Furthermore, FASN expression and activity 
are critical for AKT activation, which promotes 
cell survival and enhances tumor cell growth 
and invasiveness (45). We show here that FASN 
deficiency suppressed NLRP3 gene expression 
involving the inhibition of AKT activation in mac-
rophages. We also demonstrate that inhibition of 
p38 MAPK activation as a downstream signal of 
AKT activation by FASN deficiency reduced Il1b 
and Il18 gene expression, consistent with a pre-
vious report (59). In summary, our data demon-
strate that FASN regulates NLRP3 and pro–IL-1β 
expression via AKT and downstream p38 MAPK 
activation. Although p38 MAPK suppression 
resulted in inhibition of pro–IL-1β expression, 
we cannot exclude the partial involvement of the 
ERK1/2 MAPK signaling pathway.
We also identify here a role of FASN-dependent lipid synthesis 
in NLRP3-mediated caspase-1 activation. Fatty acids for cellular 
metabolism have two sources, exogenously derived (dietary) fatty 
acids and de novo synthesized fatty acids. Recently, it has been 
shown that exogenously derived fatty acids, such as palmitate, 
one of the most abundant fatty acids in plasma that is substantially 
elevated following a high fat diet, induces NLRP3 inflammasome 
activation (43). We showed that the inhibition of lipid synthesis 
by FASN knockdown, and by C75 treatment, suppressed NLRP3-
mediated caspase-1 activation and NLRP3 gene expression, with-
out changes in the expression of other components of the NLRP3 
inflammasome (i.e., ASC and pro–caspase-1).
In conclusion, our data suggest that UCP2 regulates NLRP3-
mediated caspase-1 activation through lipid synthesis mediated 
by FASN. Also, our data suggest that the regulation of AKT and 
downstream p38 MAPK activation by FASN are critical for NLRP3 
expression and caspase-1 activation (Figure 12 and Supplemental 
in glucose and lipid metabolites, are associated with mortality 
in patients with pneumonia and sepsis (13–15). Importantly, the 
association of high levels of blood glucose and mortality in crit-
ical care illness, including sepsis, has been described (53–55). 
These observations suggest that cellular glycolysis is upregu-
lated during septic conditions. While glycolysis is a vital met-
abolic process for cellular homeostasis, its excess activation 
induced by pathological conditions such as infection may be 
clinically deleterious for septic patients. It is generally accepted 
that hyperglycemia is associated with worse outcomes in nondi-
abetic patients who are admitted to the intensive care unit (ICU), 
and therefore it should not been neglected (56). However, the 
optimal target level of blood glucose in patients who are admit-
ted to the ICU is a highly debated topic. A single-center random-
ized controlled trial showed that a tight glucose control (target 
glucose range, 80–110 mg/dl) is linked with better survival of 
patients who are admitted to the surgical ICU compared with 
Figure 11. Inhibition of FASN activity suppresses production of IL-1β and IL-18 in vivo. (A) ELISA 
assay for IL-1β and IL-18 and (B) TG assay in the sera of wild-type mice after injection of C75  
(10 mg/kg, i.p.) or DMSO for 16 hours, followed by LPS (10 mg/kg) or PBS for 8 hours. n = 3 per 
group, *P < 0.05, **P < 0.01, ANOVA. (C) ELISA assay for IL-1β and IL-18 and (D) TG assay in the 
sera of wild-type mice after injection of cerulenin (5 mg/kg, i.p.) or DMSO for 16 hours, followed 
by LPS (10 mg/kg) or PBS for 8 hours. n = 3 per group, **P < 0.01, ANOVA. (E) Mice were injected 
with C75 (10 mg/kg, i.p.) or DMSO. After 16 hours, mice were injected with LPS (10 mg/kg, i.p.) or 
PBS. Livers were harvested after an additional 8 hours. The image depicts Oil Red O (ORO) stain-
ing for neutral lipids and lipid droplet morphology in sections from frozen liver tissues. Scale bar: 
100 μm; original magnification, ×40. n = 3 per group, **P < 0.01, ANOVA.
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nology), monoclonal rabbit anti–p44/42 MAPK (ERK1/2) antibody for 
mouse ERK1/2 (4695, Cell Signaling Technology), monoclonal rabbit 
anti–phospho-p44/42 MAPK (ERK1/2) antibody (4370, Cell Signaling 
Technology), monoclonal rabbit anti-SAPK/JNK antibody for mouse 
JNK (9258, Cell Signaling Technology), monoclonal rabbit anti–phos-
pho-SAPK/JNK antibody (4668, Cell Signaling Technology), and 
monoclonal mouse anti–β-actin antibody (A5316, Sigma-Aldrich).
Cell culture. BMDMs were prepared as described previously (3). 
Bone marrow collected from mouse femurs and tibias (male, 8–10 
weeks old) was plated on sterile petri dishes and incubated for 7 days 
in DMEM medium (Invitrogen) containing 10% (vol/vol) heat-inacti-
vated FBS, 100 units/ml penicillin, 100 mg/ml streptomycin, and 25% 
(vol/vol) conditioned medium from mouse L929 fibroblasts (CCL-1, 
ATCC). Cells were incubated for 4 hours with LPS (500 ng/ml) and 
then were treated with ATP (2 mM) for 30 minutes as described previ-
ously. Peritoneal macrophages were prepared as described previously 
(61). Mice were injected with thioglycollate broth medium (1.5 ml, i.p.). 
After 4 days, peritoneal cells were collected from mice with cold PBS. 
Cells were incubated for 2 hours with DMEM medium containing 10% 
(vol/vol) heat-inactivated FBS, penicillin, and streptomycin in 6-well 
tissue culture plates. Nonadherent cells are removed by gently wash-
ing with PBS. After cells were cultured for overnight, cells were incu-
bated for 4 hours with LPS (500 ng/ml) and then were treated with 
ATP (5 mM) for 30 minutes as described previously. Mouse J774A.1 
macrophages (TIB-67, ATCC) were cultured in DMEM medium con-
taining 10% (vol/vol) FBS, penicillin, and streptomycin.
Immunoblot analysis. Cells or tissues were harvested and lysed in 
2 × SDS loading buffer or NP40 Cell Lysis Buffer (FNN0021, Invitro-
gen) and then briefly sonicated. Lysates were centrifuged at 15,300 g 
for 10 minutes at 4°C, and the supernatants were obtained. The pro-
tein concentrations of the supernatants were determined using the 
Bradford assay (BioRad Laboratories). Proteins were subjected to 
NuPAGE 4–12% Bis-Tris gels (Invitrogen) and transferred to Protran 
nitrocellulose membranes (10600001, GE Healthcare Life Science).
Cytokine analysis. Cell culture supernatants, lung tissues, and sera 
were measured for mouse IL-1β and IL-18 with ELISA (R&D Systems). 
Cell culture supernatants, lung tissues, and sera samples were mea-
sured for mouse tumor necrosis factor with ELISA (R&D Systems).
Quantitative real-time PCR. Total RNA was isolated from cultured 
cells and tissues using the TRIzol Reagent (15596-018, Invitrogen) 
according to the manufacturer’s instructions. For the quantitative 
Figure 1). Given the roles of UCP2 in metabolic changes triggered 
by the immune response, further investigation of UCP2 in the con-
text of cellular metabolism may be useful for elucidating mecha-
nisms of human diseases, including, not just metabolic diseases, 
but diseases in which inflammation plays a key role.
Methods
Mice. The Ucp2–/– mice have been described previously (60). The lox-
UCP2 mice were generated as described previously (60). The LysM-
Cre knockin allele has a nuclear-localized Cre recombinase inserted 
into the first coding ATG of the lysozyme 2 gene (Lyz2), which abol-
ishes endogenous Lyz2 gene function and places NLS-Cre expres-
sion under the control of the endogenous Lyz2 promoter/enhancer 
elements. When crossed with a strain containing a loxP site–flanked 
sequence of interest, Cre-mediated recombination results in dele-
tion of the targeted gene in the myeloid cell lineage, including mono-
cytes, mature macrophages, and granulocytes. Macrophage-specific 
UCP2 deletion was accomplished by crossing loxUCP2 mice with 
LysM-Cre mice (The Jackson Laboratory). Mice were genotyped 
using standard PCR of tail DNA.
Reagents. LPS (E. coli) (tlrl-pelps), LAM-MS (Mycobacterium 
smegmatis) (tlrl-lams), poly(I:C) (tlrl-pic), FLA-ST (Salmonella typhi-
murium) (tlrl-pstfa), CpG oligonucleotide (tlrl-1826), and SB203580 
(tlrl-sb20) were from InvivoGen. C75 (C5490), Cerulenin (C2389), 
U0126 (U120), SP600125 (S5567), and ATP (A2383) were from Sigma- 
Aldrich. The following antibodies were used: polyclonal rabbit anti-
UCP2 for mouse UCP2 (662047, EMD Millipore), monoclonal mouse 
anti-NLRP3 for mouse NLRP3 (ALX-804-881-C100, Enzo Life Sci-
ences), polyclonal rabbit anti-ASC for mouse ASC (AP07815PU-N, 
Acris Antibodies), polyclonal goat anti–IL-1β for mouse IL-1β 
(AF-401-NA; R&D Systems), Lipid Metabolism Antibody Sampler 
Kit for anti-lipogenic enzymes (8337, Cell Signaling Technology), 
polyclonal rabbit anti-GLUT1 (ab32551; Abcam), polyclonal rabbit 
anti–caspase-1 for mouse caspase-1 (SC-514; Santa Cruz Biotechnol-
ogy), Phospho-AKT Pathway Antibody Sampler Kit for anti-AKT and 
anti–phospho-AKT (9916S, Cell Signaling Technology), monoclonal 
rabbit anti–Myc-Tag (2278, Cell Signaling Technology), polyclonal 
rabbit anti–p38 MAPK antibody for mouse p38 MAPK (9218, Cell 
Signaling Technology), polyclonal rabbit anti–p38 MAPK antibody 
for mouse p38 MAPK (9212, Cell Signaling Technology), monoclonal 
rabbit anti–phospho-p38 MAPK antibody (4511, Cell Signaling Tech-
Figure 12. Schematic of the proposed 
relationships between UCP2-
FASN–regulated lipid synthesis and 
NLRP3-mediated caspase-1 activa-
tion. Glu-6-P, glucose-6-phosphate; 
TCA, tricarboxylic acid.
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CT imaging were performed under 1.5% isoflurane general anes-
thesia. PET/CT imaging was performed for 20 minutes (10 minutes 
per bed) using a commercial micro-PET/CT scanner (eXplore Vista, 
GE healthcare), follow by a CT scan. PET images were corrected for 
random and scatter coincidence events and reconstructed with the 
ordered-subsets expectation-maximization algorithm using 16 sub-
sets and 2 iterations. No attenuation correction was applied. SUVs 
were calculated according to the formula (SUV = a / [A/W]), where 
a represents the activity concentration in the organ region of interest 
measured using PET images (Bq/ml), A represents the injected activ-
ity (Bq), and W represents the mouse body weight in grams. Blood 
and several organs were harvested for radioactivity measurement 
using a 1480 Wizard 3 γ-counter (Perkin Elmer). The PEP production 
was measured using a PEP Fluorometric Assay Kit according to the 
manufacturer’s instructions (700780, Cayman Chemical Company). 
The citrate (K655-100, BioVision) and lactate (K607-100, BioVision) 
production was measured using Colorimetric Assay Kits (BioVision) 
according to the manufacturer’s instructions.
In vivo experiments. The male mice (8–10 weeks old) were injected 
i.p. with E. coli LPS (10 mg/kg) (L4130, Sigma-Aldrich). CLP was per-
formed as previously described (63). The mice were cohoused in the 
same cages before and after CLP. The male mouse (8–10 weeks old) 
cecum was exposed through a 1.5-cm incision. The cecum was ligated 
below the ileocecal valve with a 6-0 silk suture without bowel obstruc-
tion and was then punctured with a 19-gauge needle (1-hole injury). 
Sham operation consisted of the same procedure without ligation and 
perforation of the cecum. After surgery, mice were injected with 1 ml 
physiological saline solution subcutaneously. The organ dysfunction 
was measured using the Creatinine Parameter Assay Kit (KGE005, 
R&D Systems), Aspartate Aminotransferase Activity Assay Kit 
(MAK055, Sigma-Aldrich), and Alanine Transaminase Colorimetric 
Activity Assay Kit (700260, Cayman Chemical Company).
Oil Red O staining. Neutral lipids and lipid droplet morphology 
in sections from frozen liver tissues from mice was measured by 
Oil Red O (O1391, Sigma-Aldrich) staining as described previously 
(64). The sections were incubated with the Oil Red O solution for 
5 minutes and then were counterstained with Mayer’s hematoxylin 
(MHS16, Sigma-Aldrich) for 15 seconds for visualization of the cell 
nuclei and tissue morphology. The sections were washed under run-
ning tap water for 30 minutes.
RNA extraction and microarray. We used PaxGene tubes (761115, 
QIAGEN) to collect 2.5 ml whole-blood samples from hospitalized 
patients that consented for the study. Samples were collected within 
48 hours of MICU admission (day 1). Total RNA was extracted in ran-
dom batches from all available samples using the RNeasy Mini Pro-
tocol (74104, QIAGEN). Arrays were read using the Illumina BeadAr-
ray scanner and analyzed using BeadStudio (version 3.1.7) without 
background correction. Raw expression intensities were processed 
using the Lumi package of Bioconductor, with background adjustment 
with RMA convolution, and log2 transformation of each array. The 
combined samples were quantile normalized. The complete raw and 
normalized microarray data are available through the Gene Expres-
sion Omnibus of the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/geo/, accession no. GSE32707).
Patient samples. The BWH Research Registry and Human Sample 
Repository for the Study of the Biology of Critical Illness (BWH RoCI) is 
an ongoing registry that collects demographic, clinical information, and 
RT-PCR, cDNA was synthesized from 4 μg of total RNA using ran-
dom hexamers and SuperScript Reverse Transcriptase II (18064-
014, Invitrogen) according to the manufacturer’s instructions. A 10 
μl mixture containing the diluted cDNA and a set of gene-specific 
primers was mixed with 10 μl of 2 x SYBR Green PCR Master Mix 
(4309155, Applied Biosystems) and then subjected to RT-PCR quan-
tification using the ABI PRISM 7500 Real-Time PCR System (Applied 
Biosystems). The following primers were used: mouse Il1b forward, 
5′-ATGAGAGCATCCAGCTTCAA-3′, and reverse, 5′-TGAAGGAAAA-
GAAGGTGCTC-3′; mouse Il18 forward, 5′-TCAAAGTGCCAGT-
GAACCCC-3′, and reverse, 5′-GGTCACAGCCAGTCCTCTTAC-3′; 
mouse Il12 forward, 5′-AAATGAAGCTCTGCATCCTGC-3′, and 
reverse, 5′-TCACCCTGTTGATGGTCACG-3′; mouse Tnf for-
ward, 5′-TACTGAACTTCGGGGTGATTGGTCC-3′, and reverse, 
5′-CAGCCTTGTCCCTTGAAGAGAACC-3′; mouse Nlrp3 forward, 
5′-GACGAGTGTCCGTTGCAAGCTG-3′, and reverse, 5′-TGTGGCT-
AGATCCAAGTGATCTGCC-3′; mouse Gapdh forward, 5′-GGTGAAG-
GTCGGTGTGAACGGA-3′, and reverse, 5′-CCAAAGTTGTCATG-
GATGACCTTGG-3′.
Transduction of shRNA and transfection of siRNA. For stable knock-
down of mouse Fasn, 3 independent shRNA (TRCN0000075704, 
TRCN0000075705, and TRCN0000075706, Sigma-Aldrich) were 
used. For stable knockdown of mouse p38 MAPK, 2 independent 
shRNA (TRCN0000310885 and TRCN0000304327, Sigma-Aldrich) 
were used. Mouse peritoneal macrophages (5 × 105 cells per well) 
were seeded in 6-well plates and were transduced with shRNA lenti-
viral constructs against mouse Fasn, mouse p38 MAPK, or nontarget 
shRNA (SHC016, Sigma-Aldrich) for control. For transient knock-
down of mouse Fasn, siRNA (SASI_Mm01_00177854, Sigma-Aldrich) 
was used. Mouse J774A.1 macrophages (2 × 105 cells per well) were 
seeded in 6-well plates and were transfected with siRNA for mouse 
Fasn or siRNA Universal Negative Control (SIC001, Sigma-Aldrich) 
(200 ng per well) using Lipofectamine RNAiMAX Reagent (13778-
075, Invitrogen) according to the manufacturer’s instructions. For 
overexpression of UCP2, mouse Ucp2 cDNA ORF clone (Myc-DDK-
tagged) (MR204388, OriGene Technologies) was used. Mouse J774A.1 
macrophages (2 × 105 cells per well) were seeded in 6-well plates and 
were transfected with Ucp2 cDNA ORF clone or control vector using 
Lipofectamine LTX Reagent with PLUS Reagent (15338-100, Invitro-
gen) according to the manufacturer’s instructions. For AIM2 inflam-
masome activation, LPS-primed macrophages were transfected with 
poly(dA:dT) (1 μg/ml) (P0883, Sigma-Aldrich) using Lipofectamine 
LTX Reagent with PLUS Reagent (15338-100, Invitrogen) according 
to the manufacturer’s instructions.
Glucose uptake, PEP, citrate, and lactate production assays. For a 
glucose uptake assay, cells (5 × 105 cells per well) were plated on 6-well 
plates. Cells were then incubated in a glucose-free DMEM media 
(Invitrogen) for 1 hour. After adding 18F-FDG (0.3 MBq), the cells 
were incubated at 37°C for 30 minutes. The cells were washed twice 
with PBS. Cells were harvested in PBS for radioactivity measurement 
using a 1480 Wizard 3 γ-counter (Perkin Elmer). Data shown are the 
mean ± SD of triplicate samples from a representative experiment. 
For in vivo uptake of 18F-FDG (62), male mice (8–10 weeks old) were 
starved overnight. Mice were injected i.p. with E. coli LPS (10 mg/kg) 
(L4130, Sigma-Aldrich). After LPS injection, 18F-FDG (16.7 ± 1.3 MBq) 
was administered intravenously via the tail vein. Mice were kept con-
scious for 1 hour during 18F-FDG uptake. 18F-FDG injection and PET/
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analyzed with the log-rank test. P values of less than 0.05 were consid-
ered statistically significant.
Study approval. All animal experimental protocols were approved 
by the Harvard Standing Committee for Animal Welfare (protocol no. 
04435; Harvard Medical School) and the Institutional Animal Care 
and Use Committee of Weill Cornell Medical College (New York, New 
York, USA) (protocol no. 2013-0108). All analysis of human tissue was 
conducted according to the guidelines of and with the approval of 
the BWH Institutional Review Board. BWH RoCI is approved by the 
Partners Human Research Committee and operates under protocol 
2008-P-000495. Informed consent was obtained directly from each 
subject and documented in writing before the start of study-related 
procedures. The written and oral information provided to subjects 
was approved by the Partners Human Research Committee (Boston, 
Massachusetts, USA) before and during the informed consent process.
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blood specimens from patients admitted in the MICU (11, 13, 14). All 
adults (age 18 and older) admitted to the MICU of BWH are considered 
for enrollment. Exclusion criteria included participants (a) with mental 
handicaps, (b) who are unable to provide consent or for whom an appro-
priate legal representative could not be found to provide consent, (c) 
who had previously indicated that they did not wish to be enrolled in this 
study (e.g., during a prior admission to the MICU), (d) who were admit-
ted for comfort measures and, (e) for whom there was concern about 
nonmedically indicated blood draws (e.g., Jehovah’s Witnesses). ICU 
control and sepsis was identified according to the 2001 SCCM/ESICM/
ACCP/ATS/SIS International Sepsis Definitions Conference guidelines 
(65, 66). ICU control (systemic inflammatory response syndrome) was 
defined as having 2 or more of the following criteria: temperature <36°C 
or >38°C; heart rate >90; RR interval >20 or PaCO2 <32; WBC >1,2000 
or <4,000; or >10% immature (band) forms. Sepsis was defined as a 
documented infection (culture positive or strong clinical suspicion) 
together with 2 or more ICU control criteria above. Total blood RNA was 
isolated from patients of the BWH RoCI cohort. Gene expression pro-
files were generated using Human HT-12 v4 BeadChip arrays (Illumina) 
according to the manufacturer’s protocol (15). The microarray data are 
available through the Gene Expression Omnibus of the National Center 
for Biotechnology Information (accession no. GSE32707).
Statistics. All data are mean ± SD, combined from 3 independent 
experiments. All statistical tests were analyzed by 2-tailed Student’s t 
test for comparison of 2 groups and ANOVA (with post-hoc compari-
sons using Dunnett’s test) using a statistical software package (Graph-
Pad Prism version 4.0) for comparison of multiple groups. P values of 
less than 0.05 were considered statistically significant. Survival was 
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